Trust Size
$2M
Peak Price
$390.00
Current Price
$0.13
Return
-98.7%
Price Journey
What Happened
Abpro Holdings is a biotechnology company developing next-generation multispecific antibody therapeutics for oncology and ophthalmology indications.
Abpro went public through a SPAC merger and trades under ABPO. The company is developing bispecific and multispecific antibodies for cancer treatment and eye diseases. As a pre-revenue biotech, the stock has declined significantly with a reverse stock split executed, and the company faces typical early-stage biotech funding challenges.
Timeline
2022-01-06
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1893219
Total SEC Filings
241
State of Incorporation
DE
Last Filing Date
2026-02-20
Business Location
New York, NY
Trust/Asset Size
$2M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Abpro Holdings